AbbVie Inc

11 sept 2026, 20:08 UTC

AbbVie Inc. shares are higher following positive Phase 3 LUNA study results for atogepant and strong response rates for investigational BCMA×CD3 BiTE in multiple myeloma trials.

10 sept 2026, 23:41 UTC

AbbVie Inc declared a quarterly dividend of $1.73, with a record date of October 15, 2026. Shares are higher in after-hours trading.

9 sept 2026, 23:01 UTC

AbbVie Inc. shares advanced in after-market trading, recovering from earlier lows amid broader market dynamics and rising inflation concerns linked to geopolitical tensions.

8 sept 2026, 23:06 UTC

AbbVie Inc. shares are higher in after-market hours, following a pullback earlier in the session amid broader market expectations for a Federal Reserve rate hike.

4 sept 2026, 23:05 UTC

AbbVie Inc. shares are lower in after-market hours, reflecting cautious market sentiment amid mixed economic signals and a slight uptick in the unemployment rate.

3 sept 2026, 23:11 UTC

AbbVie Inc. shares are trading higher in after-market hours following positive results from the Phase 3 CERVINO study of etentamig for multiple myeloma.

2 sept 2026, 23:51 UTC

AbbVie Inc. shares are lower in after-market trading, despite remaining above the 20-day moving average, amid a weaker-than-expected ADP payrolls report.

1 sept 2026, 23:56 UTC

AbbVie Inc. has filed for a new Skyrizi regimen to treat Crohn's disease. Shares are lower in after-market hours amid broader market pressure from rising oil prices.

31 ago 2026, 23:01 UTC

AbbVie Inc shares are higher in after-market trading, reflecting positive momentum. No specific company news was identified to explain the price movement.

28 ago 2026, 20:08 UTC

AbbVie shares are lower as the company seeks European approval for SKYRIZI. Rising U.S. Treasury yields amid inflation concerns contribute to market declines.

27 ago 2026, 23:01 UTC

AbbVie Inc. seeks European approval for SKYRIZI to treat Crohn's disease. Shares are higher in after-hours trading following a recent dip.

26 ago 2026, 23:02 UTC

AbbVie Inc shares are trading lower in after-market hours, showing volatility after Wednesday's close with no specific news identified to explain the movement.

25 ago 2026, 20:07 UTC

AbbVie Inc shares are higher, supported by favorable macro conditions and lower Treasury yields. The stock is trading near the upper end of its one-month range.

24 ago 2026, 19:36 UTC

AbbVie Inc. shares are trading lower today, having reached a session low earlier. The stock remains above its 20-day moving average.

21 ago 2026, 20:06 UTC

AbbVie Inc is set to present new data on its bispecific antibody at the 2026 World Conference on Lung Cancer, boosting investor sentiment. Shares are higher today.

20 ago 2026, 19:31 UTC

AbbVie shares are lower today, despite Piper Sandler raising its price target to $303 from $298. The decline aligns with broader sector weakness.

19 ago 2026, 23:01 UTC

AbbVie Inc. is lower in after-market trading, driven by declines in the Biotechnology sub-sector. Recent sessions had shown upward momentum.

18 ago 2026, 23:51 UTC

Abbvie Inc shares are trading higher in after-market hours, reflecting resilience amid elevated bond yields and inflation concerns. The stock remains above its 20-day moving average.

17 ago 2026, 23:51 UTC

AbbVie Inc shares are trading lower in after-market hours amid weak broader market sentiment influenced by geopolitical tensions and rising crude oil prices.

14 ago 2026, 19:46 UTC

AbbVie Inc has begun a Phase 2 trial for ABBV-295, yet shares are lower amid negative market sentiment from a decline in U.S. retail sales.

13 ago 2026, 23:21 UTC

Abbvie Inc shares are lower in after-market hours, with no specific news identified for the decline. Initial jobless claims rose unexpectedly today.

12 ago 2026, 20:06 UTC

AbbVie Inc. shares are lower today, continuing a decline since Tuesday's close, despite FDA acceptance of a BOTOX Cosmetic application for jawline contouring.

11 ago 2026, 20:06 UTC

AbbVie shares are higher as BNP Paribas raises the price target to $247. Allergan Aesthetics enhances its Partner Privileges program to boost customer engagement.

10 ago 2026, 23:06 UTC

AbbVie Inc shares are lower in after-market hours amid mixed market sentiment influenced by geopolitical tensions and President Trump's comments on economic pressure.

7 ago 2026, 23:01 UTC

AbbVie Inc shares are trading lower in after-market hours, with no specific news identified to explain the decline. The stock remains near its one-month low.

6 ago 2026, 20:06 UTC

AbbVie Inc shares are lower as bearish sentiment grows in biotech and pharma sectors, with discussions highlighting potential resistance and negative momentum patterns.

5 ago 2026, 19:26 UTC

AbbVie shares are higher as Canada's Drug Agency recommends UBRELVY for migraine treatment. The company also raised its 2026 revenue outlook to $67.60 billion.

4 ago 2026, 23:01 UTC

AbbVie Inc shares are higher in after-market hours following a recommendation for UBRELVY® reimbursement by Canada's Drug Agency, enhancing patient accessibility.

3 ago 2026, 23:06 UTC

Canaccord Genuity raised its price target for AbbVie to $290, contributing to a modest increase in shares during after-market hours.

31 jul 2026, 20:04 UTC

AbbVie Inc. lowered its 2026 adjusted earnings guidance, now projecting $13.87 to $14.07 per share, contributing to a decline in its stock price today.